CG
SLNO

Carlyle Group’s Soleno Therapeutics SLNO Stock Holding History

Carlyle Group’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-860,980
Closed -$72.1M – 21
2025
Q2 		$72.1M Hold
860,980
– – 1.43% 2
2025
Q1 		$61.4M Sell
860,980
-514,666
-37% -$25.1M 1.62% 2
2024
Q4 		$61.8M Sell
1,375,646
-2,695,916
-66% -$140M 1.49% 2
2024
Q3 		$205M Hold
4,071,562
– – 21.52% 2
2024
Q2 		$166M Hold
4,071,562
– – 15.8% 3
2024
Q1 		$173M Buy
4,071,562
+1,213,758
+42% +$54.9M 10.91% 3
2023
Q4 		$115M Buy
2,857,804
+564,242
+25% +$16.1M 5.53% 3
2023
Q3 		$67.4M Buy
2,293,562
+1,092,056
+91% +$6.61M 2.92% 5
2023
Q2 		$5.09M Hold
1,201,506
– – 0.18% 18
2023
Q1 		$2.54M Buy
+1,201,506
New +$2.7M 0.08% 23

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group's SLNO Position: Q3 2025 in Review

Carlyle Group sold out of Soleno Therapeutics (SLNO) in Q3 2025, closing a stake of 860,980 shares — an estimated $72.1M sold.

Carlyle Group first reported a position in SLNO in Q1 2023 and held it in 10 quarters. The position peaked at $205M in Q3 2024. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • Carlyle Group reported no remaining Soleno Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Carlyle Group sold 860,980 Soleno Therapeutics shares in Q3 2025, an estimated $72.1M.
  • Carlyle Group first reported a position in Soleno Therapeutics in Q1 2023 and held it in 10 quarters.
  • Carlyle Group's Soleno Therapeutics position peaked at $205M in Q3 2024.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on Carlyle Group's 13F filing for Q3 2025, filed 7 Nov 2025.